Letters, Testimony & Comments

April 3, 2007
BIO's Comments.
April 2, 2007
Comments regarding purchasing by state and local governments through Federal Supply Schedules.
March 29, 2007
Any Statutory Pathway for the Approval of Follow-On Biologics Must Protect Patient Safety and Preserve Incentives to Innovate
March 26, 2007
BIO Submits letter to Congress restating opposition to H.R. 1038.
March 15, 2007
RE: Inclusion of Prescription Drugs for Minimum Credible Coverage Dear Dr. Kingsdale: On behalf of the Biotechnology Industry Organization (BIO), I am writing regarding the Connector Board's recent endorsement of plans for Commonwealth...
March 15, 2007
BIO letter to the Commonwealth Health Insurance Connector Authority regarding the inclusion of prescription drugs for Minimum Creditable Coverage (MCC) under the Commonwealth Choice program.
March 13, 2007
Comments on the HRSA Notice
March 8, 2007
Office of the U.S. Trade Representative
March 8, 2007
BIO Submits Letter to Congress Detailing Concerns Regarding Clinton-Schumer Legislation Urges Congress to Consider Any Action on Follow-Ons Independent of PDUFA
February 20, 2007
Comments regarding the treatment of prescription drugs under the Medicaid Drug Rebate Program
February 16, 2007
The Biotechnology Industry Organization (BIO) welcomes this opportunity to comment on the success of the Prescription Drug User Fee Act (PDUFA) and the proposed enhancements for PDUFA IV. BIO represents more than 1,100 biotechnology companies,...
February 6, 2007
BIO's Comments on the Town Hall Meeting
February 1, 2007
HOUSE COMMITTEE ON ENERGY & ENVIRONMENTAL PROTECTION February 1, 2007 House Bill 1048 Relating to Genetically Modified Crops Chair Morita and members of the House Committee on Energy & Environmental Protection, I am Rick Tsujimura,...